GlassScriptPhysician profile
Victoria E White
NPI 1134574643
$2,657.95
in general payments reported to CMS, 2019-2025
26 companies · $49.22 in 2025
The $49.22 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $807 · 2023: $619 · 2024: $685 · 2025: $49.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $351.47 | 2021-2023 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $258.77 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $249.31 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.70 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $148.98 | 2022-2024 | Farxiga |
| Novo Nordisk INC | $148.68 | 2023 | Ozempic |
| Ucb, INC. | $143.36 | 2024-2025 | Rystiggo |
| Abbvie INC. | $140.24 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $139.12 | 2022 | |
| Tg Therapeutics, INC. | $130.55 | 2024 | |
| Lilly USA, LLC | $118.67 | 2024 | Amyvid, Emgality, Reyvow |
| Esperion Therapeutics, INC. | $105.27 | 2022 | |
| Edwards Lifesciences Corporation | $95.43 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Banner Life Sciences, LLC | $50.04 | 2024 | |
| Eisai INC. | $46.35 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $44.76 | 2024 | Cabenuva |
| Octapharma USA, INC. | $38.39 | 2024 | Panzyga |
| Revance Therapeutics, INC. | $34.25 | 2024 | Daxxify |
| Vanda Pharmaceuticals INC. | $29.49 | 2024 | Ponvory |
| Ipsen Biopharmaceuticals, INC | $26.26 | 2024 | Dysport |
| Allergan, INC. | $23.39 | 2022 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Amgen INC. | $18.59 | 2025 | Tezspire |
| Lundbeck LLC | $17.36 | 2024 | Vyepti |
| Abbott Laboratories | $17.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.